Table 2.
Underlying risk and comorbid condition
| Overall, N = 1341 | STEMI, N = 771 | NSTEMI, N = 571 | p-value2 | |
|---|---|---|---|---|
| HTN, n (%) | 101 (75.4) | 56 (72.7) | 45 (78.9) | 0.41 |
| DM, n (%) | 58 (43.2) | 33 (42.9) | 19 (33.3) | 0.26 |
| Both DM and HTN n (%) | 44 (32.8) | 28 (36.4) | 16 (28.1) | 0.31 |
| HBA1C, Median (IQR) | 9.0 (6.9–10.8) | 9.0 (6.9–10.6) | 8.0 (7.0–10.5) | 0.95 |
|
Categories of HBA1C n (%) < 6.5% 6.5-7% > 7% |
7(13.7) 11(21.6) 33(64.7) |
5(15.6) 6(18.8) 21(65.6) |
2(10.5) 5(26.3) 12(63.2) |
0.83 |
|
Therapy among DM, n (%) Non- Pharmacotherapy Oral Insulin Oral and insulin |
5(8.6) 31(53.4) 14(24.1) 8(13.8) |
5(12.8) 21(53.8) 7(17.9) 6(15.4) |
0(0) 10(52.6) 7(36.8) 2(10.5) |
0.24 |
| Smoking | 69 (51.5) | 43(55.8) | 26(45.6) | 0.90 |
| On Cholesterol lowering medication prior presentation, n (%) | 68 (50.7) | 33(42.9) | 35(61.4) | 0.13 |
| Previous MI, n (%) | 16 [11] | 8(10.4) | 8 [14] | 0.52 |
| Family history of Premature ASCVD, n (%) | 72(53.7) | 43(55.8) | 29(50.8) | 0.33 |
|
Other Comorbid Conditions, n (%) Hypothyroidism Hyperthyroidism CKD and ESRD HIV Connective tissue disease Asthma Polycythemia |
14(10.4) 3(2.2) 8(5.9) 3(2.2) 12(8.9) 3(2.2) 6(4.5) |
6(7.8%) 3(3.9) 2(2.6) 3(3.9) 5(6.5) 1(1.3) 5(6.5) |
8(14.1) 0(0.0) 6(10.5) 0(0) 7(12.3) 2(3.6) 1(1.8) |
0.33 |
1n (%); Median (IQR), 2Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test. HBA1C: Glycated Hemoglobin, DM: Diabetes Mellitus, HTN: Systemic arterial hypertension, MI: Myocardial Infarction, CAD: Coronary Artery Disease, ASCVD: Atherosclerotic Cardiovascular Disease CKD: Chronic Kidney Disease, ESRD: Ends stage renal disease, HIV: Human immunodeficiency Virus.